What is the ticker symbol for Pliant Therapeutics?

Pliant Therapeutics trades under the ticker PLRX on NASDAQ.

What sector does Pliant Therapeutics operate in?

Pliant Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze PLRX in a portfolio?

PortView shows PLRX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Pliant Therapeutics (PLRX) Stock Analysis

NASDAQHealthcareBiotechnology

$0.87+2.04%

1-year price historyRange $0.85 – $1.80

52-week range$0.87

$0.83$1.82

Track PLRX in your portfolio for free · Portfolio tracker

What Pliant Therapeutics does

Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.

Key metrics

Market cap

$54.16M

P/E (TTM)

-0.60

EPS (TTM)

$-1.46

Beta

1.28

Dividend yield

0.00%

Revenue / share

$0.00

50-day avg

$1.06

200-day avg

$1.17

52-week high

$1.82

52-week low

$0.83

CEO

Bernard Coulie

ETFs linked to PLRX

Broad-market and Healthcare sector ETFs an investor holding Pliant Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how PLRX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze PLRX in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Pliant Therapeutics?: Pliant Therapeutics trades under the ticker PLRX on NASDAQ.
Which exchange is PLRX listed on?: PLRX is listed on NASDAQ.
What sector does Pliant Therapeutics operate in?: Pliant Therapeutics is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze PLRX in a portfolio?: PortView shows PLRX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.